CN100430072C - Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases - Google Patents
Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN100430072C CN100430072C CNB2006100907866A CN200610090786A CN100430072C CN 100430072 C CN100430072 C CN 100430072C CN B2006100907866 A CNB2006100907866 A CN B2006100907866A CN 200610090786 A CN200610090786 A CN 200610090786A CN 100430072 C CN100430072 C CN 100430072C
- Authority
- CN
- China
- Prior art keywords
- preparation
- radix
- active substance
- pharmaceutically active
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating cardiovascular and cerebrovascular diseases is proportionally prepared from pueraria root, acanthopanax bark, earthworm and leech.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof, said preparation has benefiting QI for activating blood circulation, the eliminating blood stasis and smoothing collaterals effect.
Background technology:
Cardiovascular and cerebrovascular disease is common ailment of middle-aged and old, frequently-occurring disease, and wherein apoplexy is the modal cause of disease that disables, and apoplexy brings very big burden to family, influences the social productive forces development; Such disease acute stage,, convalescent period and sequela stage were to mark void based on this reality, and blood stasis due to qi deficiency person is more.
In recent years, along with going deep into of clinical research, also occur the Chinese medicine preparation of some treatment apoplexy on the market, but existing medicine belongs to a bit and cure the symptoms, not the disease, some uses expensive composition, and some interrupts use because uncertain therapeutic efficacy is cut in application process.
In view of this, the inventor develop a kind of taking convenience, effect steadily, determined curative effect, dosage form be stable, quality controllable, and the pure Chinese medicinal preparation that has no side effect is to satisfy the demand of extensive patients.
For this reason, the invention provides a kind of new recipe, the present invention selects Radix Et Caulis Acanthopanacis Senticosi, Radix Puerariae, Pheretima, Hirudo four flavor Chinese prescriptions, be prepared into and have benefiting QI for activating blood circulation, eliminating blood stasis and smoothing collaterals, the compound Chinese medicinal preparation of the function of arteriosclerosis, blood vessel dilating, coronary blood flow increasing is applicable to cerebral infarction, thoracic obstruction syndrome of blood stasis due to qi deficiency, and disease is seen not smoothgoing puckery, the crooked mouth and tongue of hemianesthesia, pain, hemiplegia, speech, spiritlessness and weakness, hypomnesis, insomnia, coronary heart disease etc.
Radix Et Caulis Acanthopanacis Senticosi acrid in the mouth, little hardship, warm in nature among the side of the present invention have the effect of replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization, blood circulation promoting and blood stasis dispelling.Be monarch drug; Pheretima, salty in the mouth, cold in nature, the collateral dredging of passing through is arrogated to oneself diseases such as controlling passages through which vital energy circulates is obstructed, hemiplegia.Radix Puerariae sweet in the mouth, suffering, property is flat.Expelling pathogenic factors from muscles arranged, promote the production of body fluid, the yang invigorating function, arrogate to oneself wind headache in the treatment.Be ministerial drug altogether; Hirudo salty in the mouth, hardship, property is flat, returns Liver Channel, and merit is apt to removing blood stasis.Share with Pheretima, strengthen the merit of activating blood circulation to dissipate blood stasis and dredge the collateral, be adjuvant drug.All medicines share, and vital energy benefiting and the kidney invigorating is calmed the nerves, the merit of blood circulation promoting and blood stasis dispelling collateral dredging and play altogether.
Summary of the invention:
The invention provides a kind of treatment cardiovascular and cerebrovascular disease Chinese medicine preparation, the function of said preparation cures mainly as follows: benefiting QI for activating blood circulation, eliminating blood stasis and smoothing collaterals.Cerebral infarction (cerebral infarction) convalescent period, card belonged to blood stasis due to qi deficiency, and disease is seen not smoothgoing puckery, the crooked mouth and tongue of hemianesthesia, pain, hemiplegia, speech, spiritlessness and weakness, hypomnesis, insomnia, coronary heart disease etc.
The invention provides a kind of treatment cardiovascular and cerebrovascular disease Chinese medicine preparation, said preparation is made by following Chinese medicine raw materials by weight proportion:
Radix Puerariae 672-2688 part
Radix Et Caulis Acanthopanacis Senticosi 672-2688 part
Pheretima 504-2016 part
Hirudo 168-672 part
Preferably:
1344 parts of Radix Puerariaes
1344 parts of Radix Et Caulis Acanthopanacis Senticosis
1008 parts of Pheretimas
336 parts of Hirudos
In more than forming, part is a weight portion, and the weight of each medicine of distinguishing the flavor of is calculated with crude drug, if weight portion is unit with the gram, above-mentioned prescription composition can be made into pharmaceutical preparation 500-2000 agent.Described 1 dose of finger, the final drug preparation of making, as make capsule preparations 500-2000 grain, and tablet 500-2000 sheet, granule 500-2000g, oral liquid 500-2000ml, unguentum 500-2000g etc., but preferred 1000 doses.
More than form being by weight as proportioning, can increasing or reduce according to corresponding proportion when producing, can be unit with kg as large-scale production, or is unit with t (ton); Preparation can be unit with g also on a small scale.Weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant substantially.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine medical material that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by co-extracted raw material of Chinese medicine medical material, also can obtain by other modes, as: by pulverize, squeeze, grind, sieve, method such as percolation, extraction, water are carried, alcohol extraction, ester are carried, chromatography obtains, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutical preparation of the present invention, the pharmaceutical dosage forms of unit dose preferably, can make any pharmaceutically useful dosage form when making pharmaceutical preparation, these dosage forms are selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, injection, suppository, ointment, plaster, cream, spray, patch.Oral formulations form preferably, the best is tablet preferably, capsule, granule.
Pharmaceutical preparation of the present invention, its pharmaceutically active substance makes through extracting processing, and processing method is as follows:
Fang Zhongsi flavor, Radix Puerariae adds 5 times of amount 80% ethanol, the heating and refluxing extraction secondary, each 3 hours, merge extractive liquid, filtered, filtrate recycling ethanol, the thick paste that is concentrated into relative density and is 1.28～1.30 (60 ℃ of surveys) is standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi add 8 times of water gagings, decoct secondary, each 2 hours, collecting decoction filters, and being concentrated into relative density is 1.28～1.30 (60 ℃ of surveys), merge with above-mentioned standby thick paste, promptly form pharmaceutically active substance of the present invention, this active substance mixes with the medicine acceptable carrier, promptly can be made into Chinese medicine preparation of the present invention according to the galenic pharmacy routine techniques.
Pharmaceutical preparation of the present invention can add some medicine acceptable carriers as required, can adopt the galenic pharmacy routine techniques to prepare this pharmaceutical preparation, as pharmaceutically active substance is mixed with the medicine acceptable carrier.The acceptable carrier of described medicine is selected from: mannitol, sorbitol, sorbic acid or potassium salt, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitamin C, vitamin E, vitamin D, azone, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, soil temperature 60-80, span-80, Cera Flava, lanoline, liquid paraffin, hexadecanol, gallate ester, agar, triethanolamine, basic amino acid, carbamide, allantoin, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Pharmaceutical preparation of the present invention is determined usage and dosage according to patient's situation in use.
Chinese medicine preparation of the present invention, when making medicament, the medicament of unit dose can contain pharmaceutically active substance 0.1-1000mg of the present invention, and all the other are pharmaceutically acceptable carrier.Pharmaceutically acceptable carrier can be the 0.1-99.9% of total formulation weight amount by weight.
The most preferred prescription of the present invention is listed in the embodiment of the invention.
Preparation of the present invention has been carried out pharmacodynamics test, and the result is as follows:
Preparation called after trematodiasis dragon removing obstruction from collaterals pill wherein of the present invention.
1. adopt the Multitest method that trematodiasis dragon removing obstruction from collaterals pill has been carried out the pharmacology evaluation of cerebral ischemia aspect, the result shows, set up rat medium-sized artery (MCA) focal cerebral ischemia model by line bolt method, after administration, rat nerve injury symptom is had some improvement, and can reduce brain water content, reduce the cerebral ischemia scope, reduce the cerebral ischemia degree, the cerebral tissue ischemia of pathological changes is improved.Same this medicine is cerebral blood flow increasing amount and reduction cerebral vascular resistance and total peripheral resistance obviously, but blood pressure, heart rate there is not obvious influence, this product also can reduce whole blood contrast viscosity, plasma viscosity, packed cell volume and the platelet aggregation intensity of blood stasis model animal simultaneously, and inhibition thrombosis length and weight, this product also can prolong blood coagulation time and cerebral ischemia mice time-to-live, the function of blood vessel dilating, coronary blood flow increasing in addition.
2. The acute toxicity tests
Trematodiasis dragon removing obstruction from collaterals pill 65% concentration press 40ml/kg for mice disposable (single medication) and is irritated stomach (ig), mice activity as a result freely, diet is normal, observes continuously 7 days, obviously showing does not unusually appear in animal, none death of animal is so inferior single-dose LD
50Can't measure.Ig is continuous 2 times in 1 day, observes 7 days continuously after the administration, and none Mus death was put to death mice in the 8th day, cutd open inspection, does not see that organizing the obvious abnormal change of internal organs, result to record the maximum dosage of mice ig this product is 52g/kg.
3. long term toxicity test result
Test is got the Wistar rat and is divided into three dosage groups (trematodiasis dragon removing obstruction from collaterals pill high dose group, middle dosage group, low dose group), a blank group, by setting dosage administration every day 1 time, continuous use 6 months, observe the general state situation of animal behind the medicine, periodic logging body weight, appetite, after administration 3 months, 6 months and the drug withdrawal 15 days, each puts to death 10 animals, and carries out hematology, blood biochemical and reach histopathologic examination substantially.The result, during the administration, through visual examination, each treated animal activity, hair color, behavior, food-intake, body weight, urine, just all Non Apparent Abnormality changes, each treated animal is not seen untoward reaction, the weight increase amount, food-intake is all normal, and to administration 3 months, administration 6 months and convalescent hematology's conventional index (RBC, WBC, Hb, PLT, leaflet, lymph, MCHC, MCH, MCV and clotting time), blood parameters (ALT, AST, BUN, TP, ALB, ALP, GLU, T-CHO, CRE, TBIL) mensuration, administration group and matched group compare P all＞0.05.Cut open behind the sacrifice of animal core, internal organs such as liver, spleen, lung, kidney, adrenal gland, thymus, brain, prostate, testis, epididymis, uterus, ovary weigh, calculate organ coefficient, data result shows that medication group and matched group compare, the statistical procedures there was no significant difference.Get stomach, duodenum, ileum, colon, hypophysis, oblongata, breastbone, lymph, bladder, pancreas, optic nerve, thyroid simultaneously and do the histopathology cut sections for microscopic examination together with internal organs than 25 internal organs such as internal organs, the result does not see and organizes internal organs that the pathological change relevant with medicine arranged.
Preparation of the present invention has been carried out the clinical trial of part, and the result is as follows:
Preparation called after trematodiasis dragon removing obstruction from collaterals pill wherein of the present invention.
1. clinical data
1.1 this group case is inpatient, male 18 examples, women 12 examples; 39～78 years old age, average 65.3 years old.The standard that clinical diagnosis is formulated with reference to the 4th the cerebrovascular academic conference in the nineteen ninety-five whole nation, and the Cerebral Infarction Patients that confirms through head CT or MRI, apoplexy tcm diagnosis standard: meet traditional Chinese medical science blood stasis due to qi deficiency, venation block card simultaneously with reference to " apoplexy diagnosis, efficacy assessment standard " (Chinese Chinese medicine association Society of Internal Medicine formulate in June, 1986).Main symptom: hemiplegia, facial hemiparalysis, stiff tongue speech is not smoothgoing or in silence, hemianesthesia; Hold concurrently with spiritlessness and weakness, lip and nail are purple dark, brothers' swelling, dimly pale tongue or the purple stasis of blood, the purple stasis of blood are arranged, venation stasis of blood purple at the bottom of the tongue, hesitant pulse or thin string.
Neurological deficit scoring 15 ± 7.8 minutes, 2 thoughtful 4 weeks of the course of disease, average 19.1 ± 6.3 days; Basal ganglia region cerebral infarction 17 examples, multiple cerebral infarction 9 examples, cortex is blocked 3 examples, and pon blocks 1 example.Wherein concurrent hypertension 20 examples, concurrent diabetes 7 examples, coronary heart disease atrial fibrillation 2 examples.
1.2. Therapeutic Method:
Side's medicine is formed: Radix Et Caulis Acanthopanacis Senticosi 12g, Radix Puerariae 12g, Pheretima 9g, Hirudo 3g.
Method of administration: conventional decoction decoction is 300ml altogether, every clothes 150ml, twice of every day.Hypertension, diabetes routine are taken corresponding Western medicine, do not take other treatment cerebrovascular Chinese and western drugs.
The course of treatment: 4 weeks.
1.3 efficacy assessment standard.
With reference to clinical neurologic deficit degree standards of grading and the curative effect determinate standard that the 4th national cerebrovascular meeting of Chinese Medical Association formulated, judge curative effect according to the variation and the viability state (0 grade～7 grades of invalid degree) of the neurologic impairment value for the treatment of.
Be almost recovered: the functional impairment scoring reduces 91%～100%, and invalid degree is 0 grade
Marked improvement:: the functional impairment scoring reduces 46%～90%, and invalid degree is 1～3 grade
Progressive:: the functional impairment scoring reduces 18%～45%
No change: the functional impairment scoring reduces about 17%
Worsen: the functional impairment scoring reduces or increases more than 18%
Dead.
(2) tcm syndrome curative effect scoring method
Hemianesthesia does not have 0 fen
Slight numb, flickering 1 minute
Moderate, between weight 2 minutes
Severe, depth sensation obviously
Do not know sufferings even go down 3 minutes
Brothers' swelling does not have 0 fen
Gently, may be seen indistinctly 1 fen
Moderate, visible 2 minutes
Heavy, very obvious 3 minutes
The purple dark nothing of lip and nail 0 minute
Duskiness 1 minute
Dark 2 minutes
Purple dark 3 minutes
Normal 0 minute of body of the tongue
Secretly, the petechia ecchymosis there is 1 minute
Normal 0 minute of pulse condition
Hesitant pulse or thin string 1 minute
.2 result
Table 1 efficacy result
Result of study shows that we have the effect that recovers nervous function preferably, and obvious effective rate reaches 56.7%, has
Efficient is 93.3%, and can obviously improve the tcm clinical practice syndrome.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
The preparation of tablet:
Trematodiasis dragon removing obstruction from collaterals pill prescription:
Radix Puerariae 1344g
Radix Et Caulis Acanthopanacis Senticosi 1344g
Pheretima 1008g
Hirudo 336g
The about 50g of starch
Magnesium stearate is an amount of
Make 1000
Method for making: Fang Zhongsi flavor, Radix Puerariae adds 5 times of amount 80% ethanol, the heating and refluxing extraction secondary, each 3 hours, merge extractive liquid, filtered, filtrate recycling ethanol, the thick paste that is concentrated into relative density and is 1.28～1.30 (60 ℃ of surveys) is standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi add 8 times of water gagings, decoct secondary, and each 2 hours, collecting decoction, filter, being concentrated into relative density is 1.28～1.30 (60 ℃ of surveys), merges with above-mentioned standby thick paste, drying under reduced pressure (0.08Mpa, 80 ℃) is ground into fine powder (crossing 80 mesh sieves), add the about 50g of starch, with 90% ethanol system granule, 50 ℃ of dryings, it is an amount of to add magnesium stearate, mixing, tabletting, the bag film-coat is made 1000, promptly.
Embodiment 2
The granule preparation:
Trematodiasis dragon collateral dredging granule prescription:
Radix Puerariae 1344g
Radix Et Caulis Acanthopanacis Senticosi 1344g
Pheretima 1008g
Hirudo 336g
The about 50g of starch
Magnesium stearate is an amount of
Make 1000g
Method for making: Fang Zhongsi flavor, Radix Puerariae adds 5 times of amount 80% ethanol, the heating and refluxing extraction secondary, each 3 hours, merge extractive liquid, filtered, filtrate recycling ethanol, the thick paste that is concentrated into relative density and is 1.28～1.30 (60 ℃ of surveys) is standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi add 8 times of water gagings, decoct secondary, each 2 hours, collecting decoction filters, and being concentrated into relative density is 1.28～1.30 (60 ℃ of surveys), merge drying under reduced pressure (0.08Mpa, 80 ℃) with above-mentioned standby thick paste, be ground into fine powder (crossing 80 mesh sieves), add the about 50g of starch, sucrose 50g, with 90% ethanol system granule, 50 ℃ of dryings, the adding magnesium stearate is an amount of, mixing is made the 1000g granule.
Embodiment 3
The capsule preparation:
Trematodiasis dragon capsule for freeing collateral vessels prescription:
Radix Puerariae 1344g
Radix Et Caulis Acanthopanacis Senticosi 1344g
Pheretima 1008g
Hirudo 336g
The about 50g of starch
Magnesium stearate is an amount of
Make 1000
Method for making: Fang Zhongsi flavor, Radix Puerariae adds 5 times of amount 80% ethanol, the heating and refluxing extraction secondary, each 3 hours, merge extractive liquid, filtered, filtrate recycling ethanol, the thick paste that is concentrated into relative density and is 1.28～1.30 (60 ℃ of surveys) is standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi add 8 times of water gagings, decoct secondary, each 2 hours, collecting decoction filters, and being concentrated into relative density is 1.28～1.30 (60 ℃ of surveys), merge drying under reduced pressure (0.08Mpa, 80 ℃) with above-mentioned standby thick paste, be ground into fine powder (crossing 80 mesh sieves), add the about 50g of starch, with 90% ethanol system granule, 50 ℃ of dryings, it is an amount of to add magnesium stearate, mixing, encapsulated 1000.
Embodiment 4
The preparation of tablet:
Trematodiasis dragon removing obstruction from collaterals pill prescription:
Radix Puerariae 672g
Radix Et Caulis Acanthopanacis Senticosi 672g
Pheretima 504g
Hirudo 168g
The about 50g of starch
Magnesium stearate is an amount of
Make 1000
Method for making: Fang Zhongsi flavor, Radix Puerariae adds 5 times of amount 80% ethanol, the heating and refluxing extraction secondary, each 3 hours, merge extractive liquid, filtered, filtrate recycling ethanol, the thick paste that is concentrated into relative density and is 1.28～1.30 (60 ℃ of surveys) is standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi add 8 times of water gagings, decoct secondary, and each 2 hours, collecting decoction, filter, being concentrated into relative density is 1.28～1.30 (60 ℃ of surveys), merges with above-mentioned standby thick paste, drying under reduced pressure (0.08Mpa, 80 ℃) is ground into fine powder (crossing 80 mesh sieves), add the about 50g of starch, with 90% ethanol system granule, 50 ℃ of dryings, it is an amount of to add magnesium stearate, mixing, tabletting, the bag film-coat is made 1000, promptly.
Embodiment 5
The preparation of tablet:
Trematodiasis dragon removing obstruction from collaterals pill prescription:
Radix Puerariae 2688g
Radix Et Caulis Acanthopanacis Senticosi 2688g
Pheretima 2016g
Hirudo 672g
The about 50g of starch
Magnesium stearate is an amount of
Make 1000
Method for making: Fang Zhongsi flavor, Radix Puerariae adds 5 times of amount 80% ethanol, the heating and refluxing extraction secondary, each 3 hours, merge extractive liquid, filtered, filtrate recycling ethanol, the thick paste that is concentrated into relative density and is 1.28～1.30 (60 ℃ of surveys) is standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi add 8 times of water gagings, decoct secondary, and each 2 hours, collecting decoction, filter, being concentrated into relative density is 1.28～1.30 (60 ℃ of surveys), merges with above-mentioned standby thick paste, drying under reduced pressure (0.08Mpa, 80 ℃) is ground into fine powder (crossing 80 mesh sieves), add the about 50g of starch, with 90% ethanol system granule, 50 ℃ of dryings, it is an amount of to add magnesium stearate, mixing, tabletting, the bag film-coat is made 1000, promptly.
Claims (9)
1, a kind of treatment cardiovascular and cerebrovascular disease Chinese medicine preparation is characterized in that, is made by following Chinese medicine raw materials by weight proportion medical material:
Radix Puerariae 672-2688 part
Radix Et Caulis Acanthopanacis Senticosi 672-2688 part
Pheretima 504-2016 part
Hirudo 168-672 part.
2, the preparation of claim 1 is characterized in that, is made by following Chinese medicine raw materials by weight proportion medical material:
1344 parts of Radix Puerariaes
1344 parts of Radix Et Caulis Acanthopanacis Senticosis
1008 parts of Pheretimas
336 parts of Hirudos.
3, the preparation of claim 1, it is characterized in that dosage form is selected from: tablet, capsule, oral liquid, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, injection, suppository, ointment, plaster, spray or patch.
4, the preparation method of the preparation of claim 1 is characterized in that, is to extract by the raw material of Chinese medicine medical material process that the prescription of claim 1 is formed, and makes pharmaceutically active substance; Subsequently, be raw material with this material, add the medicine acceptable carrier when needing, make according to the routine techniques of galenic pharmacy.
5, the preparation method of claim 4 is characterized in that, wherein said pharmaceutically active substance preparation method is as follows: Radix Puerariae adds ethanol extraction, filters, and filtrate recycling ethanol concentrates standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi decoct with water, and filter, and concentrate, and merge with above-mentioned standby thick paste, promptly form pharmaceutically active substance.
6, the preparation method of claim 4 is characterized in that, further comprises described pharmaceutically active substance is mixed with the medicine acceptable carrier, makes the step of Chinese medicine preparation according to the galenic pharmacy routine techniques.
7, the preparation method of claim 4 is characterized in that, the preparation method of tablet is as follows:
Prescription:
1344 parts of Radix Puerariaes
1344 parts of Radix Et Caulis Acanthopanacis Senticosis
1008 parts of Pheretimas
Hirudo 336
Radix Puerariae adds ethanol extraction, filters, and filtrate recycling ethanol concentrates standby; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi decoct with water, and filter, and concentrate, and merge with above-mentioned standby thick paste, promptly form pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, promptly can be made into tablet according to the galenic pharmacy routine techniques.
8, the preparation method of claim 5, it is characterized in that, wherein said pharmaceutically active substance preparation method is as follows: the Fang Zhongsi flavor, and Radix Puerariae adds 5 times of amount 80% ethanol, the heating and refluxing extraction secondary, each 3 hours, merge extractive liquid, filtered, filtrate recycling ethanol, it is standby to be concentrated into relative density and to be 1.28～1.30 thick paste; Three flavors such as Radix Et Caulis Acanthopanacis Senticosi add 8 times of water gagings, decoct secondary, and each 2 hours, collecting decoction filtered, and being concentrated into relative density is 1.28～1.30, merge with above-mentioned standby thick paste, promptly form pharmaceutically active substance.
9, the preparation method of claim 8 is characterized in that, further comprises described pharmaceutically active substance is mixed with the medicine acceptable carrier, makes the step of Chinese medicine preparation according to the galenic pharmacy routine techniques.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100907866A CN100430072C (en) | 2006-06-30 | 2006-06-30 | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100907866A CN100430072C (en) | 2006-06-30 | 2006-06-30 | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895341A CN1895341A (en) | 2007-01-17 |
| CN100430072C true CN100430072C (en) | 2008-11-05 |
Family
ID=37608079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100907866A Active CN100430072C (en) | 2006-06-30 | 2006-06-30 | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100430072C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488765B (en) * | 2011-12-16 | 2013-11-27 | 王立财 | Medicine for treating osseous rheumatism and cerebral apoplexy |
| CN104547929B (en) * | 2015-01-08 | 2017-12-19 | 荆州市民康生物科技有限公司 | A kind of Chinese medicine and preparation method for treating apoplexy sequelae |
-
2006
- 2006-06-30 CN CNB2006100907866A patent/CN100430072C/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 中药单方、提取物及单纯化合物治疗冠心病心绞痛的研究进展. 李巨奇等.现代中西医结合杂志2000，第9卷第22期. 2000 |
| 中药单方、提取物及单纯化合物治疗冠心病心绞痛的研究进展. 李巨奇等.现代中西医结合杂志2000，第9卷第22期. 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1895341A (en) | 2007-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102512521A (en) | Traditional Chinese medicine composition for treating apoplexy sequela | |
| CN101199618A (en) | Shenling know luo capsule | |
| CN1330345C (en) | Combination of Chinese traditional medicine for treating hyperlipemia, and preparation method | |
| CN100430072C (en) | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases | |
| CN101584796A (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN105434738A (en) | Traditional Chinese medicine composition for treating ADHD (Attention Deficit Hyperactivity Disorder) and preparation method thereof | |
| CN1331504C (en) | Medicine for treating coronary heart disease and angina pectoris and its prepn | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN102526444A (en) | Traditional Chinese medicine composition for invigorating kidney and strengthening yang and preparation method thereof | |
| CN101618131A (en) | Chinese medicinal compound preparation for treating coronary heart disease and angina | |
| CN102028834B (en) | Compound Longxueji preparation and preparation method thereof | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN101244139B (en) | Chinese medicine composition for prevention or adjuvant therapy of cardiovascular disease and method of preparing the same | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN104689151A (en) | Traditional Chinese medicine composition for treating diabetes and use of composition | |
| CN103961646A (en) | Traditional Chinese medicinal preparation composition for nourishing qi and yin and activating blood circulation to remove stasis | |
| CN103272146A (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN1528436A (en) | Chinese medicine preparation using rhizoma gastrodiae and eucommia as main material and preparing method thereof | |
| CN109045240B (en) | Traditional Chinese medicine composition of Gaocheng preparation, preparation method, detection method and application thereof | |
| CN100482264C (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN1507906A (en) | Medicine for treating cardio-cerebro vascular disease and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: FANGSHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING TONGYU KANGTAI TECHNOLOGY CO., LTD. Effective date: 20130912 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100086 HAIDIAN, BEIJING TO: 410205 CHANGSHA, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130912 Address after: 410205 Hunan province Changsha City West Lu Tin Road No. 19 Patentee after: Hunan Fangsheng Pharmaceutical Co.,Ltd. Address before: 100086, room 1708G, Qingyun contemporary building, No. 43 West Third Ring Road, Haidian District, Beijing Patentee before: Beijing Tongyu Kangtai Technology Co., Ltd. |